Up-regulation of circadian clock gene Period 2 in the prostate mesenchymal cells during flutamide-induced apoptosis

Yoshida, Kaoru

Department of Animal and Marine Bioresource Sciences, Faculty of Agriculture, Kyushu University

He, Pei-Jian

Department of Medicine, Emory University School of Medicine | Department of Animal and Marine Bioresource Sciences, Faculty of Agriculture, Kyushu University

Yamauchi, Nobuhiko

Department of Animal and Marine Bioresource Sciences, Faculty of Agriculture, Kyushu University

Hashimoto, Seiichi

Molecular Medicine Research Laboratories, Drug Discovery Research, Astellas Pharma Inc. |
Department of Technology Development, Innovation Headquarters, Japan Science and Technology Agency

他

<http://hdl.handle.net/2324/26624>

出版情報 : Molecular and Cellular Biochemistry. 335 (1/2), pp.37-45, 2010-02-01. Springer US
バージョン :
権利関係 : (C) Springer Science+Business Media, LLC. 2009

TITLE:

Up-regulation of circadian clock gene Period 2 in the prostate mesenchymal cells during flutamide-induced apoptosis

AUTHORS AND AFFILIATIONS:

Kaoru Yoshida¹, Pei-jian He¹§, Nobuhiko Yamauchi¹, Seiichi Hashimoto²# and Masa-aki Hattori¹*

¹Department of Animal and Marine Bioresource Sciences, Faculty of Agriculture, Kyushu University, Fukuoka-shi, Fukuoka 812-8581; ²Molecular Medicine Research Labs, Drug Discovery Research, Astellas Pharma Inc, Miyukigaoka 21, Tsukuba-shi, Ibaraki 305-8585, Japan

*CORRESPONDENCE to: Masa-aki Hattori

Phone & FAX: +81-92-642-2938, E-mail address: mhattori@agr.kyushu-u.ac.jp

§Present address: Department of Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA

Present address: Department of Technology Development, Innovation Headquarters, Japan Science and Technology Agency, 5-3, Yobanchou, Chiyoda-ku, Tokyo 102-8666, Japan.

Abstract

Androgen regulates the proper development and physiological function of the prostate. Here we investigated on the modulation of androgen and androgen receptor (AR) antagonist on circadian oscillations of a clock core gene *Period 2* (*Per2*) in rat prostate mesenchymal cells (PMCs). Circadian oscillations were analyzed with the real-time monitoring system of gene expression using transgenic rats introduced with mouse *Per2* promoter fused to a destabilized luciferase (*Per2-dLuc*) reporter gene. Analyses of circadian oscillations, immunofluorescence and androgen response element (ARE)-luciferase reporter assay revealed that circadian clocks are operative and the AR protein is functional in PMCs in vitro. Androgen such as testosterone and dihydrotestosterone did not cause any changes in circadian *Per2-dLuc* oscillations of confluent cells. Conversely, flutamide (FL) up-regulated the amplitude of circadian *Per2-dLuc* oscillations in a dose-dependent manner, whereas testosterone antagonized the action of FL. The PER2 protein was markedly accumulated by FL treatment and localized in both the nucleus and cytoplasm during the first peak period of circadian *Per2-dLuc* oscillations. Simultaneously, FL treatment increased apoptotic cell death. Collectively, the present study demonstrates that a clock gene *Per2* is up-regulated in PMCs during FL-induced apoptotic cell death. Thus, circadian oscillations of *Per2* gene expression may be closely linked to the cellular states of PMCs such as apoptotic cell death.

Key words

Period 2; *Per2-dLuc* oscillations; prostate mesenchymal cells; flutamide; androgen; apoptosis

Introduction

Physiology, pathology and metabolism in mammals are influenced by circadian rhythms, which are integrated by the master pacemaker located in the suprachiasmatic nucleus (SCN) of the hypothalamus [1]. At the molecular level, the pacemaker is composed of transcriptional and translational feedback core loops. The CLOCK and BMAL1, associated as heterodimers, bind to canonical E-Box cis-elements, and positively drive the expression of the *Period* genes (*Per1*, *Per2* and *Per3*) and *Cryptochrome* genes, whose proteins, in turn, form multimeric complexes and feed back to repress the transactivation by CLOCK/BMAL1 in the nucleus [1-3].

The master pacemaker synchronizes the peripheral circadian clocks through complex interaction of neural, humoral, and behavioral cues [4, 5]. Autonomic circadian clocks are also operative in various peripheral tissues including the heart, liver, kidney, lung, spleen, adrenal gland, skeletal muscles [6, 7], and uterus [8-11]. In contrast, thymocytes, Leydig cells, and ovarian immature granulosa cells [12-16] lack their functions. So far, the identification of resetting cues and their regulatory effects on circadian clocks are mostly based on molecular biological studies in cultured cell lines. A variety of factors have been unraveled having the potential to reset circadian clocks in peripheral cells [17-23]. Glucocorticoid, for example, can efficiently activate *Per1* expression and synchronize circadian oscillations of clock genes in cultured cells, also being able to phase-shift the circadian rhythms in peripheral tissues [19]. In the rat

Per2 gene, many regulatory cis-elements are in the upstream from its transcription start site, such as estrogen response cis-element (ERE)-half and progestin/glucocorticoid/androgen response cis-element (PRE/GRE/ARE)-half sites as well as E-Box and D-Box cis-elements. Our recent studies have indicated that both estradiol (E2) and progesterone (P4) up-regulate *Per2* gene expression, and P4 especially plays a pivotal role in the circadian clocks of the uterus endometrial stromal cells [10, 11]. Steroid hormones may be regulators for circadian oscillations of clock genes in the hormone target tissues.

Androgens play an important role in the proper development and physiological function of the prostate [24, 25]. In the prostate mesenchymal (PMCs) and epithelial cells, the action of testosterone (T) or dihydrotestosterone (DHT) is initiated by their binding to the intracellular androgen receptor (AR). Then, the androgen-bound receptor complex binds to AREs in the promoter regions of target genes, and transcriptional regulation occurs in a ligand-dependent manner. Since both T and DHT modulate the growth of normal and malignant prostate tissues, androgen ablation and antiandrogen hormonal therapy, including flutamide (FL), are effective for the early-stage prostate cancer [26, 27]. Recent studies have reported that down-regulation of *Per2* gene expression accelerates breast cancer growth by altering its circadian oscillations [28] and *Per2* overexpression induces apoptosis in murine lung and breast cancer cell lines [29]. However, there is little literature concerning the steroid hormone

regulation of circadian clocks in the prostate. From these recent studies, we can raise the intriguing possibility of androgen and AR antagonist participation in the modulation of circadian oscillations of clock genes in the normal prostate cells.

Here we focus on the modulation of androgen and AR antagonist on circadian oscillations of a clock core gene *Per2* in rat PMCs in vitro. The real-time monitoring system of gene expression was employed to evaluate circadian clocks using transgenic rats constructed with mouse *Per2* promoter-destabilized luciferase (*Per2-dLuc*) reporter gene [30]. In the present study, we extend our recent studies to prove the differential roles of androgen and an AR antagonist FL in circadian clocks of PMCs. Our results proved up-regulation of clock gene *Per2* in PMCs during FL-induced apoptotic cell death.

Materials and methods

Chemicals

T, FL, DHT, dexamethasone (DXM), forskolin, D-luciferin sodium salt, and Hoechst were purchased from Sigma Chemical (St. Louis, MO). DMEM/F12, collagenase (type I), DNase I, hyaluronidase, and penicillin-streptomycin (PS) were from GIBCO (Grand Island, NY), and propidium iodide (PI) was from Dojindo (Kumamoto, Japan). Fetal bovine serum (FBS) was from BioSource International (Camarillo, CA), and treated with dextran-coated charcoal. Anti-PER2 (H-90) and anti-AR polyclonal antibodies

were from Santa Cruz Biotechnology (Santa Cruz, CA), and anti-rabbit IgG conjugated with fluorescein was from Leinco Technologies (St. Louis, MO).

Animals

All the experiments were performed under the control of the Guideline for Animal Experiment in Faculty of Medicine, Kyushu University and The Law (No. 105) and Notification (No. 6) of the Government. Mouse *Per2* promoter region (chr1 (-): 93289505-93293019 on the Build 36 assembly by NCBI and the Mouse Genome Sequencing Consortium) was fused to a *dLuc* reporter gene [30]. *Per2-dLuc* transgenic rats were generated in accordance with the method described in the patent publication number WO/2002/081682 (Y.S. New Technology Institute, Utsunomiya, Japan). Transgenic and normal rats were maintained under 12-h light and 12-h dark (light between 0800 and 2000) with water and food *ad libitum*.

Preparation and culture of PMCs

PMCs were prepared from mature rats as described previously [31], with slight modifications. Briefly, small pieces of ventral prostates were washed 3 times with sterile PBS, and treated at 37°C for 20 min in a shaking water bath in PBS containing 1 mg/ml collagenase, 1 µg/ml DNase I, 10 µM EGTA, and 0.1% bovine serum albumin (BSA). Then, small pieces of ventral prostates treated were incubated at 37°C for 30

min in a shaking water bath in PBS containing 1 mg/ml collagenase, 1 µg/ml DNase I, 1 mg/ml hyaluronidase, 10 µM EGTA, and 0.1% BSA. The dispersed clumps of cells and single cells were passed through 80-µm stainless mesh and the fragments were dispensed. The harvested cells were washed 3 times with phenol red free DMEM/F12 containing 10% charcoal-treated FBS and 1% PS and seeded onto 35-mm collagen-coated dishes (IWAKI, Chiba, Japan) at the density of 2×10^5 cells/dish/2 ml. After incubation for 3 days at 37°C, PMCs attached to the dish and floating epithelial cells were removed. Cultured PMCs were positively immunostained for vimentin (a marker protein of mesenchymal cells), with approximately 95%, but negatively for cytokeratin (a marker of epithelial cells). After a 6-day culture, confluent cells were subjected to real-time monitoring of circadian oscillations.

ARE-luciferase constructs in PMCs

The ARE was constructed as follows: sense oligonucleotide, 5'-CGCG (AGC ACA TCG TGC TCA)₆-3'; antisense oligonucleotide, 5'-GATC (TGA GCA CGA TGT GCT)₆-3'. The oligonucleotides were annealed, and inserted into the *MluI* and *BglII* sites of the pGL3-promoter luciferase reporter vector digested with the corresponding restriction enzymes. The constructed plasmid was transformed into JM 109 cells, replicated and extracted with Endo-free Plasmid Preparation Kit (Qiagen). The plasmid was transfected into subconfluent PMCs with LipofectAMINE-2000 reagent [32].

Upon the onset of bioluminescent measurement (time 0 h), PMCs were given in replaced fresh medium supplemented with 5% charcoal-treated FBS, 1% PS, 15 mM HEPES, 0.1 mM luciferin, and T (1, 10 μ M) or vehicle. Luciferase activity was chronologically monitored at 37°C with Kronos AB-2500 (ATTO, Tokyo, Japan).

Real-time monitoring of circadian oscillations

Upon the onset of bioluminescent measurement (time 0 h), cultured PMCs were given in replaced fresh medium supplemented with 5% charcoal-treated FBS, 1% PS, 15 mM HEPES, 0.1 mM luciferin, and various concentrations of T, DHT, or FL dissolved in absolute ethanol, with final ethanol concentration of below 0.01%. Cultured PMCs were also treated with 0.1 μ M DXM or 1 μ M forskolin as previously reported [15]. Monitoring of bioluminescence was performed for 4 days at 37°C using Kronos AB-2500 interfaced to computer for continuous data acquisition as previously described [10, 15, 16].

Immunofluorescence analysis

The ventral prostate sections at 8- μ m thickness were fixed for 5 min in acetone at -20°C. Nonspecific binding was blocked using 2% goat serum in PBS (blocking buffer) for 30 min. Sections were incubated for 12-18 h at 4°C with anti-PER2 and anti-AR antibodies diluted in blocking buffer. After washing with PBS, they were

incubated with the second antibody for 1 h at room temperature (RT). Sections were subsequently washed in PBS and mounted with Mount-Quick Aqueous (Daido Sangyo, Japan). Cultured PMCs were washed 3 times with PBS, fixed with 4% paraformaldehyde at RT for 20 min, and treated for 30 min with 0.1% Triton X-100-PBS, and incubated in blocking buffer at RT for 30 min. PMCs were incubated at 4°C at 24 h with anti-PER2 antibody diluted in PBS containing 2% goat serum. After washing, cells were treated for 1 h at RT with PBS containing anti-rabbit IgG conjugated with fluorescein and 0.1 µg/ml Hoechst. PMCs were washed 3 times with PBS, and immunostaining was detected under a fluorescence microscope (Nikon, Japan).

Cell death

Cultured PMCs were washed twice with PBS, and incubated at 37°C for 20 min with PBS containing 5 µg/ml PI and 10 µg/ml Hoechst. After washing twice with PBS, Hoechst-positive (total cells) and PI-positive cells (apoptotic cells) were counted under a fluorescence microscope.

Statistical analyses

The quantification of immunofluorescence staining intensity was performed as previously reported [33]. A box was drawn through each compartment in a random

orientation, and the pixel value of each box was measured by NIH Scion Image. A mean value was obtained from the determination of more than twenty boxes for each sample. All the experiments were independently repeated at least 3 times, and data were expressed as means $\pm$ SE. The differences between them were evaluated using Student's t test. A P value < 0.05 was considered to be statistically significant.

Results

Expression of PER2 and AR proteins in PMCs

Immunofluorescent analysis using the prostates of mature rats was performed to evaluate the expression and subcellular localization of the PER2 and AR proteins. Weak immunostaining of the PER2 protein was observed in the mesenchyme, and relatively strong staining in the epithelium (Fig. 1b). The AR protein was expressed in both the mesenchyme and epithelium, especially distributed in the nuclei of both compartments (Fig. 1c). In the merged image, both the PER2 and AR proteins were detected in the mesenchyme (Fig. 1d). No staining was observed in the negative control (data not shown). The response to androgen was assessed using ARE-Luc constructs in PMCs. As the results are shown in Fig. 2, following a minor activity prior to 24 h, there was a major peak in bioluminescence activity after 24-48 h of stimulation with T (1, 10 μ M), showing a dose-dependent manner. Immunostaining of the AR protein was also detected in cultured PMCs. Consequently, the AR protein is functional

in PMCs in vitro.

Circadian Per2-dLuc oscillations in PMCs

PMCs prepared from transgenic rats were stimulated with or without DXM or forskolin, and subjected to monitoring of *Per2-dLuc* oscillation. As the results are shown in Fig. 3, the amplitude of oscillations was increased after exposure to either DXM or forskolin, as compared to that given by vehicle only. PMCs generated oscillations with approximately 24 h per cycle, although the amplitude was gradually decreasing. Thus, circadian clocks are operative in PMCs in vitro.

Effects of androgens and FL on circadian Per2-dLuc oscillations in PMCs

The effects of T, DHT, and FL on *Per2-dLuc* oscillations were analyzed. PMCs were stimulated with or without reagents (each 1 μ M), and subjected to monitoring of *Per2-dLuc* oscillation. Circadian oscillations were not significantly altered after treatment with T or DHT (Fig. 4A). In contrast, FL up-regulated the amplitude of oscillations. The first (P1) and second (P2) peaks of *Per2-dLuc* oscillations in FL-treated cells were significantly higher than those given by treatment with T or DHT ($P<0.05$) (Fig. 4B). However, there was no significant difference in the first (T1) and second (T2) troughs among all the treatments. The action of FL (0.1-10 μ M) was assessed for its dose-dependency. As the results are shown in Fig. 5A, FL increased the

amplitude of oscillations, although no activity was generated at 0.1 μ M. When the first peaks of circadian oscillations were calculated, the action of FL occurred in a dose-dependent manner (Fig. 5B).

Competitive inhibitory effect of T on FL-induced circadian Per2-dLuc oscillations in PMCs

The effect of T on FL-induced *Per2-dLuc* oscillations was analyzed. PMCs were pretreated for 5 h with increasing concentrations of T (0.1-10 μ M), and given in replaced fresh medium supplemented with 1 μ M FL, and then subjected to monitoring of oscillation. As the results are shown in Fig. 6, the pretreatment with 10 μ M T caused a significant decrease in the first peak of circadian oscillations stimulated by FL, showing the competitive inhibitory effect of T on the action of FL.

Immunofluorescent analysis of PER2 in PMCs in vitro

To further investigate the effect of FL on circadian rhythms of the PER2 protein, immunofluorescent studies were performed to analyze for its expression and localization in PMCs. In control PMCs, PER2 immunostaining was slightly higher in the first peak (34 h) than in the first trough (48 h), with several strongly stained cells (Fig. 7b, arrowheads). In the FL-treated PMCs, PER2 immunostaining was much stronger in the first peak than in the first trough. In the first peak, many cells were

strongly stained, and round and small in size, that apoptotic cell death was induced (Fig. 7i, arrowheads). In the first peak of both cell groups, the PER2 staining signal was detected in both the nucleus and cytoplasm (Fig. 7c, g, j and n), whereas the signal was not in the cytoplasm in the first trough (Fig. 7f, m). No staining was observed in the negative control (data not shown). From the immunofluorescence observation, changes of PER2 staining intensity in PMCs were calculated by NIH Scion Image (Table 1). The intensity at P1 was 2.5-fold of that given by the control. Also, the intensity at T1 was significantly higher than that given by the control.

Analysis of apoptosis in PMCs

To confirm apoptotic cell death, PMCs were cultured for 34 h (P1) and 48 h (T1) with 1 μ M FL and subjected to PI staining. As the results are shown in Fig. 8, treatment with FL caused a marked increase in cell death, with 2.5-fold over the control in both P1 and T1.

Discussion

Several studies have demonstrated that circadian core clock genes Per1 and Per2 are rhythmically expressed in the steroid target tissues [8-11]. The purpose of this study is to analyze the regulation of circadian clocks in PMCs by androgen and AR antagonist.

Immunofluorescent analysis and ARE-luciferase reporter assay revealed that both the PER2 and functional AR proteins were expressed in the mesenchyme, although the PER2 protein was highly expressed in the epithelial cell layer. In addition, PMCs generated strong circadian oscillations after exposure to DXM or forskolin in vitro, indicating that circadian clocks are operative.

It was next investigated if circadian clocks are influenced by androgen such as T and DHT in PMCs in vitro. Unexpectedly, both T and DHT did not cause any changes in circadian oscillations. T and DHT could bind to their receptor, which, in turn, interacts with its target cis-element in the promoters of target genes, thereby regulating gene transcription [34]. Other steroid hormones can differentially modulate circadian clocks in peripheral tissues. E2 does not induce circadian oscillations in the uterus stromal cells, whereas P4 promotes the rhythmic pattern [10, 11]. Chronic treatment with E2 also disrupts circadian oscillations of *Per1* and *Per2* expression in the liver, kidney and uterus [8]. On the other hand, FL is generally used as an AR antagonist for therapy of prostate cancer [35]. Interestingly, FL dose-dependently up-regulated the amplitude of circadian oscillations in PMCs in vitro. Since the E-Box cis-elements in the *Per2* promoter are essential for the binding of CLOCK/BMAL1 and generation of circadian oscillations [36, 37], FL may promote the transcription of the *Per2* gene through direct or indirect transactivation of CLOCK/BMAL1. Immunofluorescent studies were performed to analyze for PER2 expression and localization in PMCs.

During the first peak in FL-treated cells, the PER2 staining signal was detected in both the nucleus and cytoplasm, and thereafter the signal was drastically decreased in the cytoplasm during the first trough. These findings may indicate that the negative feedback loop by multimeric complexes of Period and Cryptochrome proteins is still functional in survived PMCs after FL treatment. Anyway, our present results indicate that FL is an inducer for overexpression of the *Per2*. Conversely, T could antagonize the action of FL. There are several reports that FL behaves as a partial agonist. FL modulates AR activity and DJ-1 in the human prostate epithelial cells [38], and also activates AR phosphorylation for expression of prostate-specific antigen in the normal prostate cell lines [39]. The agonistic action of FL may be related to SMRT (silencing mediator of retinoid and thyroid hormone receptor) and N-CoR corepressors (nuclear receptor corepressor) involved in transcriptional regulation by both agonist- and antagonist-bound AR [39]. However, if our present data resulted from the agonistic action of FL in PMCs, both T and DHT should be expected to up-regulate circadian *Per2* gene oscillations. Recent studies also reported the AR-independent action of FL [40, 41]. FL activates the expression of protein kinase C isoenzymes in CSS-LNCaP cells and can elicit responses in prostate cancer cells that do not express AR [40]. In the rat prostate, apoptosis is suppressed by binding of decoy receptor DcR2 to TNF- α -related apoptosis-inducing ligand and is induced through the decoy receptor inhibited by FL [41]. Taken together with our present data, up-regulation of circadian

oscillations by FL may result from both AR-dependent and -independent pathways.

Analyses of circadian oscillations using the *Per2-dLuc* reporter gene and immunocytochemical studies demonstrated that FL also up-regulates the PER2 protein in PMCs. Strongly immunostained cells in the first peak of circadian oscillations appeared to apoptotic cell death. These apoptotic cells were observed as small particles during the first trough. Consequently, FL-induced apoptosis may be closely related to overexpression of the PER2 protein. Several studies reported that the *Per2* gene not only modulates circadian oscillations, but also regulates cellular function. The *Per2* gene is reported to be tumor suppressor gene [42] and circadian disruption may increase the risk of breast cancer [43, 44]. Overexpression of the PER2 protein induces apoptosis in the mouse Lewis lung carcinoma cell line and mammary carcinoma cell line [29, 45]. Conversely, down-regulation of *Per2* expression accelerates the growth of breast cancer [28]. Thus, overexpression of the PER2 protein may be linked to apoptotic cell death in normal as well as several cancer cells.

Acknowledgments

This research was supported in part by a Grant-in-Aid for Scientific Research (B) from Japan Society for the Promotion of Sciences (JSPS; no.17658131; to M-A H).

References

1. Reppert SM, Weaver DR (2001) Molecular analysis of mammalian circadian rhythms. *Annu Rev Physiol* 63:647–676.
2. Shearman LP, Sriram S, Weaver DR, Maywood ES, Chaves I, Zheng B, Kume K, Lee CC, van der Horst GT, Hastings MH, Reppert SM (2000) Interacting molecular loops in the mammalian circadian clock. *Science* 288:1013–1019.
3. Ueda HR, Hayashi S, Chen W, Sano M, Machida M, Shigeyoshi Y, Iino M, Hashimoto S (2005) System-level identification of transcriptional circuits underlying mammalian circadian clocks. *Nat Genet* 37:187–192.
4. Damiola F, Le Minh N, Preitner N, Kornmann B, Fleury-Olela F, Schibler U (2000) Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. *Genes Dev* 14:2950–2961.
5. Schibler U, Sassone-Corsi P (2002) A web of circadian pacemakers. *Cell* 111:919–922.
6. Yamamoto T, Nakahata Y, Soma H, Akashi M, Mamme T, Takumi T (2004) Transcriptional oscillation of canonical clock genes in mouse peripheral tissues. *BMC Mol Biol* 5:18.
7. Lemos DR, Downs JL, Urbanski HF (2006) Twenty-four-hour rhythmic gene

expression in the rhesus macaque adrenal gland. *Molecular Endocrinology* 20:1164–1176.

8. Nakamura TJ, Moriya T, Inoue S, Shimazoe T, Watanabe S, Ebihara S, Shinohara K (2005) Estrogen differentially regulates expression of *Per1* and *Per2* genes between central and peripheral clocks and between reproductive and nonreproductive tissues in female rats. *J Neurosci Res* 82:622–630.
9. Dolatshad H, Campbell EA, O'Hara L, Maywood ES, Hastings MH, Johnson MH (2006) Developmental and reproductive performance in circadian mutant mice. *Hum Reprod* 21:68–79.
10. He PJ, Hirata M, Yamauchi N, Hattori M-A (2007a) Up-regulation of *Per1* expression by estradiol and progesterone in the rat uterus. *J Endocrinol* 194:511–519.
11. Hirata M, He PJ, Shibuya N, Uchikawa M, Yamauchi N, Hashimoto S, Hattori M-A (2009) Progesterone, but not estradiol, synchronizes circadian oscillator in the uterus endometrial stromal cells. *Mol Cell Biochem* 324:31–38.
12. Morse D, Cermakian N, Brancorsini S, Parvinen M, Sassone-Corsi P (2003) No circadian rhythms in testis: *Period1* expression is clock independent and developmentally regulated in the mouse. *Mol Endocrinol* 17:141–151.
13. Alvarez JD, Chen D, Storer E, Sehgal A (2003) Non-cyclic and developmental stage-specific expression of circadian clock proteins during murine

spermatogenesis. *Biol Reprod* 69:81–91.

14. Alvarez JD, Sehgal A (2005) The thymus is similar to the testis in its pattern of circadian clock gene expression. *J Biol Rhythms* 20:111–121.
15. He PJ, Hirata M, Yamauchi N, Hashimoto S, Hattori M-A (2007b) The disruption of circadian clockwork in differentiating cells from rat reproductive tissues as identified by in vitro real-time monitoring system. *J Endocrinol* 193:413–420.
16. He PJ, Hirata M, Yamauchi N, Hashimoto S, Hattori M-A (2007c) Gonadotropic regulation of circadian clockwork in rat granulosa cells. *Mol Cell Biochem* 302:111–118.
17. Akashi M, Ichise T, Mamme T, Takumi T (2006) Molecular mechanism of cell-autonomous circadian gene expression of *Period2*, a crucial regulator of the mammalian circadian clock. *Mol Biol Cell* 17:555–565.
18. Balsalobre A, Brown SA, Marcacci L, Tronche F, Kellendonk C, Reichardt HM, Schutz G, Schibler U (2000a) Resetting of circadian time in peripheral tissues by glucocorticoid signaling. *Science* 289:2344–2347.
19. Balsalobre A, Marcacci L, Schibler U (2000b) Multiple signaling pathways elicit circadian gene expression in cultured Rat-1 fibroblasts. *Curr Biol* 10:1291–1294.
20. Tsuchiya Y, Minami I, Kadotani H, Nishida E (2005) Resetting of peripheral circadian clock by prostaglandin E₂. *EMBO Rep* 6:256–261.
21. Hinoi E, Ueshima T, Hojo H, Iemata M, Takarada T, Yoneda Y (2006)

Up-regulation of per mRNA expression by parathyroid hormone through a protein kinase A-CREB-dependent mechanism in chondrocytes. *J Biol Chem* 281:23632–23642.

22. Nakahata Y, Akashi M, Trcka D, Yasuda A, Takumi T (2006) The in vitro real-time oscillation monitoring system identifies potential entrainment factors for circadian clocks. *BMC Mol Biol* 7:5.
23. Shirai H, Oishi K, Ishida N (2006) Circadian expression of clock genes is maintained in the liver of Vitamin A-deficient mice. *Neurosci Lett* 398:69–72.
24. McKeehan WL, Adams PS, Fast D (1987) Different hormonal requirements for androgen-independent growth of normal and tumor epithelial cells from rat prostate. *In Vitro Cell Dev Biol* 23:147–152.
25. Lu J, Danielsen M (1998) Differential regulation of androgen and glucocorticoid receptors by retinoblastoma protein. *J Biol Chem* 273:31528–31533.
26. Catalona WJ (1994) Management of cancer of the prostate. *New Engl J Med* 331: 996–1004.
27. Xing RH, Rabbani SA (1999) Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo. *Endocrinology* 140:4056–4064.
28. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG (2005) Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. *Carcinogenesis*

26: 1241–1246.

29. Hua H, Wang Y, Wan C, Liu Y, Zhu B, Yang C, Wang X, Wang Z, Cornelissen-Guillaume G, Halberg F (2006) Circadian gene mPer2 overexpression induces cancer cell apoptosis. *Cancer Sci* 97:589–596.
30. Ueda HR, Chen W, Adachi A, Wakamatsu H, Hayashi S, Takasugi T, Nagano M, Nakahama K, Suzuki Y, Sugano S, Iino M, Shigeyoshi Y, Hashimoto S (2002) A transcription factor response element for gene expression during circadian night. *Nature* 418:534–539.
31. Ravindranath N, Dym M (1999) Isolation of rat ventral prostate basal and luminal epithelial cells by the STAPUT technique. *Prostate* 41:173–180.
32. Sato F, Kurokawa M, Yamauchi N, Hattori M-A (2006) Gene silencing of myostatin in chicken embryonic myoblasts by small interfering RNA. *Am J Physiol* 291:C538–C545.
33. Han SJ, Tsai SY, Tsai MJ, O'Malley BW (2007) Distinct temporal and spatial activities of RU486 on progesterone receptor function in reproductive organs of ovariectomized mice. *Endocrinology* 148:2471–2486.
34. Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. *Endocr Rev* 25:276–308.
35. Pu Y, Huang L, Birch L, Prins GS (2007) Androgen regulation of prostate morphoregulatory gene expression: Fgf10-dependent and -independent pathways.

Endocrinology 148:1697–1706.

36. Darlington TK, Wager-Smith K, Ceriani MJ, Staknis D, Gekakis N, Steeves TDL, Weitz CJ, Takahashi JS, Kay SA. 1998 Closing the circadian loop: CLOCK-induced transcription of its own inhibitors per and tim. *Science* 280:1599–1603.
37. Travnickova-Bendova Z, Cermakian N, Reppert SM, Sassone-Corsi P (2002) Bimodal regulation of mPeriod promoters by CREB-dependent signaling and CLOCK/BMAL1 activity. *Proc Natl Acad Sci USA* 99:7728–7733.
38. Pitkanen-Arsiola T, Tillman JE, Gu G, Yuan J, Roberts RL, Wantroba M, Coetzee GA, Cookson MS, Kasper S (2006) Androgen and anti-androgen treatment modulates androgen receptor activity and DJ-1 stability. *Prostate* 66:1177–1193.
39. Yoon HG, Wong J (2006) The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor. *Mol Endocrinol* 20:1048–1060.
40. Montalvo L, Carmena MJ, Bolanos O, Rodriguez-Henche N, Sanchez-Chapado M, Prieto JC (2004) Effects of the antiandrogen flutamide on the expression of protein kinase C isoenzymes in LNCaP and PC3 human prostate cancer cells. *Biosci Rep* 24:11–21.
41. Vindrieux D, Reveiller M, Florin A, Blanchard C, Ruffion A, Devonec M,

- Benahmed M, Grataroli R (2006) TNF- α -related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate. *J Cell Physiol* 206:709–717.
42. Fu L, Pelicano H, Liu J, Huang P, Lee C (2002) The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. *Cell* 111: 41–50.
 43. Stevens RG, Rea MS (2001) Light in the built environment: potential role of circadian disruption in endocrine disruption and breast cancer. *Cancer Causes Control* 12: 279–287.
 44. Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T (2005) Period3 structural variation: a circadian biomarker associated with breast cancer in young women. *Cancer Epidemiology Biomarkers Prev* 14:268–270.
 45. Gery S, Virk RK, Chumakov K, Yu A, Koeffler HP (2007) The clock gene Per2 links the circadian system to the estrogen receptor. *Oncogene* 26:7916–7920.

Figure legends

Fig. 1. Immunofluorescence analysis for the PER2 and AR proteins in the rat prostate.

a: Prostate sections stained with Hoechst. The square region shown in **a** is magnified from a serial section subjected to immunofluorescence studies as shown in **b** and **c**. **b:** Immunostaining with anti-PER2 antibody (red) on a section of prostate. **c:** Immunostaining with anti-AR antibody (green) on a section of prostate. **d:** PER2 and AR proteins merged image. Bars: 250 μm (**a**), 50 μm (**b-d**)

Fig. 2. ARE-luciferase reporter assay in isolated PMCs. A: ARE-constructed pGL3-promoter luciferase reporter plasmid was transfected to PMCs. At time 0 h, cells were given in replaced fresh medium supplemented with 0.1 mM luciferin and T (1, 10 μM) or vehicle (as a control). B: Immunofluorescence analysis for the AR proteins in the cultured PMCs. a, Bright view. b. Immunostaining with anti-AR antibody (green). Scale bars: 150 μm .

Fig. 3. Generation of circadian Per2-dLuc oscillations in PMCs. At time 0 h, cells were given in replaced fresh medium supplemented with 0.1 mM luciferin, and 0.1 μM DXM, 1 μM forskolin or vehicle (as a control).

Fig. 4. Profiles of circadian Per2-dLuc oscillations in PMCs treated with androgens or FL. At time 0 h, cells were given in replaced fresh medium supplemented with 0.1 mM luciferin, and T, DHT, FL (each 1 μ M) or vehicle (as a control). A: Real-time bioluminescent activity was monitored in PMCs treated with vehicle, T, DHT or FL. P1-3: first to third peaks, T1-2: first to second troughs. B: The peaks and troughs were normalized to the values of the control cells treated with vehicle and data are means $\pm$ SE of three determinations. Values with different letters are significantly different ($P<0.05$).

Fig. 5. Dose-dependent increases in the amplitude of circadian Per2-dLuc oscillations in PMCs treated with FL. At time 0 h, cells were given in replaced fresh medium supplemented with 0.1 mM luciferin, and FL (0.1, 1, 10 μ M) or vehicle (as a control). A: Real-time bioluminescent activity was monitored in PMCs treated with vehicle or FL. B: Each first peak was normalized to the values of the control cells treated with vehicle and data are means $\pm$ SE of three determinations. Values with different letters are significantly different ($P<0.05$).

Fig. 6. Inhibitory effects of T on the amplitude of circadian Per2-dLuc oscillations in PMCs treated with FL. Cultured PMCs were treated with increasing concentrations of T (0.1, 1, 10 μ M) or vehicle (as a control). At time 0 h, cells were given in replaced

fresh medium supplemented with 0.1 mM luciferin, T (same concentrations), and 1 μ M FL or vehicle (as a control). A: Real-time bioluminescent activity was monitored in PMCs treated with FL and T. B: Each first peak was normalized to the values of the control cells treated with vehicle and data are means $\pm$ SE of three determinations. Values with different letters are significantly different ($P < 0.05$).

Fig. 7. Immunofluorescence analysis of PER2 protein in PMCs treated with or without FL during circadian Per2-dLuc oscillations. (Panels a-g) Images were taken from PMCs treated with vehicle at the first peak (P1) (34 h) (a-c, g) and first trough (T1) (48 h) (d-f) of circadian oscillations. (Panels h-n) Images were taken from PMCs treated with FL at the first peak (P1) (34 h) (h-j, n) and first trough (T1) (48 h) (k-m) of circadian oscillations. (Panels g and n) Magnified PER2 protein and Hoechst staining merged images in the square regions shown in panels c and j. In FL-treated cells, especially apoptotic cells were detected (arrowheads). red: PER2 protein, blue: Hoechst. Scale bars: 150 μ m.

Fig. 8. Determination of apoptotic cell death in PMCs cultured with or without FL. PMCs were treated with 1 μ M FL or vehicle (as a control) and taken at the first peak (P1) (34 h) and first trough (T1) (48 h) of circadian oscillations. PMCs were subjected to PI staining (apoptotic cells) and Hoechst staining (total cells). Data are means $\pm$ SE

of three determinations. *, $P < 0.05$ versus control.

Table 1. Changes of PER2 staining intensity in PMCs treated with or without FL during circadian Per2-dLuc oscillations as revealed by immunofluorescence.

The experiments were independently repeated at least 3 times, and data were expressed as means $\pm$ SE. Different letters are significant ($P < 0.05$).

Treatment	Position	PER2 staining intensity (Arbitrary units)
Control	P1	35.62 ± 2.11 a
	T1	21.31 ± 0.47 b
Flutamide	P1	89.83 ± 9.67 c
	T1	23.89 ± 0.38 d

FIG. 1

FIG. 2

FIG. 3

FIG. 4

FIG. 5

FIG. 6

FIG. 7

FIG. 8